• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肝性脑病：病理生理学与治疗选择的最新进展

Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options.

作者信息

Elwir Saleh, Rahimi Robert S

机构信息

Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, USA.

出版信息

J Clin Transl Hepatol. 2017 Jun 28;5(2):142-151. doi: 10.14218/JCTH.2016.00069. Epub 2017 May 4.

DOI:10.14218/JCTH.2016.00069
PMID:28660152
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5472935/
Abstract

Hepatic encephalopathy is a spectrum of reversible neuropsychiatric abnormalities, seen in patients with liver dysfunction and/or portosystemic shunting. One of the most debilitating complications of cirrhosis, encephalopathy affects 30-45% of cirrhotics. In addition to significantly affecting the lives of patients and their caregivers, it is also associated with increased morbidity and mortality as well as significant utilization of health care resources. In this paper, we provide an overview on the pathophysiology, diagnosis, management and newer therapies of hepatic encephalopathy.

摘要

肝性脑病是一系列可逆的神经精神异常，见于肝功能不全和/或门体分流的患者。作为肝硬化最使人衰弱的并发症之一，肝性脑病影响30%-45%的肝硬化患者。除了显著影响患者及其照料者的生活外，它还与发病率和死亡率增加以及医疗资源的大量使用有关。在本文中，我们概述了肝性脑病的病理生理学、诊断、管理和新疗法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a22b/5472935/a6cb20cf541b/JCTH-5-142-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a22b/5472935/beab32a7a852/JCTH-5-142-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a22b/5472935/a6cb20cf541b/JCTH-5-142-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a22b/5472935/beab32a7a852/JCTH-5-142-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a22b/5472935/a6cb20cf541b/JCTH-5-142-g002.jpg

相似文献

1
Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options.肝性脑病：病理生理学与治疗选择的最新进展
J Clin Transl Hepatol. 2017 Jun 28;5(2):142-151. doi: 10.14218/JCTH.2016.00069. Epub 2017 May 4.
2
Prophylaxis of hepatic encephalopathy: current and future drug targets.预防肝性脑病：当前和未来的药物靶点。
Hepatol Int. 2024 Aug;18(4):1096-1109. doi: 10.1007/s12072-024-10647-9. Epub 2024 Mar 16.
3
Rifaximin in the treatment of hepatic encephalopathy.利福昔明治疗肝性脑病
Hepat Med. 2011 Dec 22;3:109-17. doi: 10.2147/HMER.S11988.
4
Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.显性肝性脑病：当前的药物治疗及改善临床结局。
Am J Med. 2021 Nov;134(11):1330-1338. doi: 10.1016/j.amjmed.2021.06.007. Epub 2021 Jul 7.
5
Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.演变的概念：轻微肝性脑病的负面影响和肝硬化患者预防的作用。
Clin Ther. 2013 Sep;35(9):1458-73. doi: 10.1016/j.clinthera.2013.07.421. Epub 2013 Aug 22.
6
Management of hepatic encephalopathy in the hospital.医院中肝性脑病的管理。
Mayo Clin Proc. 2014 Feb;89(2):241-53. doi: 10.1016/j.mayocp.2013.11.009. Epub 2014 Jan 8.
7
Hepatic Encephalopathy: Diagnostic Tools and Management Strategies.肝性脑病：诊断工具与管理策略
Med Clin North Am. 2023 May;107(3):517-531. doi: 10.1016/j.mcna.2023.01.003. Epub 2023 Feb 20.
8
Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.利福昔明联合乳果糖与单用乳果糖治疗肝性脑病的比较。
J Assoc Physicians India. 2017 Aug;65(8):42-46.
9
Sodium benzoate for treatment of hepatic encephalopathy.苯甲酸钠用于治疗肝性脑病。
Gastroenterol Hepatol (N Y). 2013 Apr;9(4):219-27.
10
Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.原发性护理中肝硬化的并发症：肝性脑病的识别与管理。
Am J Med Sci. 2018 Sep;356(3):296-303. doi: 10.1016/j.amjms.2018.06.008. Epub 2018 Jun 19.

引用本文的文献

1
The Change of Noncoding RNA Expression in Olfactory Bulb of Hepatic Encephalopathy Mouse Model: Transcriptomic Analysis and Cellular Analysis.肝性脑病小鼠模型嗅球中非编码RNA表达的变化：转录组分析和细胞分析
CNS Neurosci Ther. 2025 Sep;31(9):e70596. doi: 10.1111/cns.70596.
2
Therapeutic Duel of Rifaximin Versus Lactulose in Hepatic Encephalopathy: A Systematic Review.利福昔明与乳果糖治疗肝性脑病的疗效对比：一项系统评价
Cureus. 2025 Jun 17;17(6):e86193. doi: 10.7759/cureus.86193. eCollection 2025 Jun.
3
Unraveling the Gut-Liver-Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches.

本文引用的文献

1
Hepatic Encephalopathy.肝性脑病
N Engl J Med. 2016 Oct 27;375(17):1660-1670. doi: 10.1056/NEJMra1600561.
2
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.质子泵抑制剂增加肝硬化患者肝性脑病风险：一项基于人群的研究。
Gastroenterology. 2017 Jan;152(1):134-141. doi: 10.1053/j.gastro.2016.09.007. Epub 2016 Sep 14.
3
Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites.
解析肠-肝-脑轴：微生物群、炎症及新兴治疗方法
Mediators Inflamm. 2025 Jun 18;2025:6733477. doi: 10.1155/mi/6733477. eCollection 2025.
4
Successful portosystemic shunt embolization resolves hepatic encephalopathy and enhances hepatic function and glycemic control in MASH-related cirrhosis: a case report.成功的门体分流栓塞术可缓解肝性脑病，并改善MASH相关肝硬化患者的肝功能和血糖控制：一例报告
Clin J Gastroenterol. 2025 Feb;18(1):137-144. doi: 10.1007/s12328-024-02074-y. Epub 2024 Dec 23.
5
Effect of an Autotaxin Inhibitor, 2-(4-Chlorophenyl)-7-methyl-8-pentylimidazo[1,2-] Pyrimidin-5(8)-one (CBT-295), on Bile Duct Ligation-Induced Chronic Liver Disease and Associated Hepatic Encephalopathy in Rats.自分泌运动因子抑制剂2-(4-氯苯基)-7-甲基-8-戊基咪唑并[1,2 -]嘧啶-5(8)-酮（CBT-295）对胆管结扎诱导的大鼠慢性肝病及相关肝性脑病的影响
ACS Pharmacol Transl Sci. 2024 Aug 13;7(9):2662-2676. doi: 10.1021/acsptsci.4c00066. eCollection 2024 Sep 13.
6
From Cirrhosis to the Dysbiosis (A Loop of Cure or Complications?).从肝硬化到菌群失调（治愈还是并发症的循环？）
Indian J Microbiol. 2024 Sep;64(3):810-820. doi: 10.1007/s12088-024-01267-w. Epub 2024 Apr 3.
7
Advances in the management of complications from cirrhosis.肝硬化并发症管理的进展
Gastroenterol Rep (Oxf). 2024 Aug 5;12:goae072. doi: 10.1093/gastro/goae072. eCollection 2024.
8
Investigation of Post-Transplant Mental Well-Being in Liver Transplant Recipients with Hepatic Encephalopathy.肝性脑病肝移植受者移植后心理健康状况调查
J Clin Med. 2024 May 31;13(11):3249. doi: 10.3390/jcm13113249.
9
Alcoholism and Socioeconomic Status among Patients with Hepatic Encephalopathy in Association with Increased Mortality.肝性脑病患者的酒精中毒与社会经济地位及其与死亡率增加的关系
Addict Health. 2024 Feb;16(1):1-5. doi: 10.34172/ahj.2024.1467. Epub 2024 Feb 29.
10
Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease.急性肝衰竭和慢性肝病中的肠道微生物群与神经炎症
Metabolites. 2023 Jun 20;13(6):772. doi: 10.3390/metabo13060772.
质子泵抑制剂作为肝硬化伴腹水患者肝性脑病和自发性细菌性腹膜炎的危险因素。
Hepatology. 2016 Oct;64(4):1265-72. doi: 10.1002/hep.28737. Epub 2016 Aug 24.
4
Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France.在法国，与标准治疗相比，利福昔明-α给药用于减少显性肝性脑病复发发作的成本效益分析。
Therap Adv Gastroenterol. 2016 Jul;9(4):473-82. doi: 10.1177/1756283X16644249. Epub 2016 May 1.
5
Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice.肠道微生物群驱动小鼠肝硬化中神经炎症反应的发展。
Hepatology. 2016 Oct;64(4):1232-48. doi: 10.1002/hep.28696. Epub 2016 Jul 29.
6
Overuse of Head Computed Tomography in Cirrhosis With Altered Mental Status.肝硬化伴精神状态改变时头颅计算机断层扫描的过度使用
Am J Med Sci. 2016 May;351(5):459-66. doi: 10.1016/j.amjms.2016.02.022. Epub 2016 Feb 17.
7
Management of Hepatic Encephalopathy: A Primer.肝性脑病的管理：入门指南。
Ann Pharmacother. 2016 Jul;50(7):569-77. doi: 10.1177/1060028016645826. Epub 2016 Apr 28.
8
Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia Concentration.肝硬化伴肝性脑病患者应用苯丁酸钠甘油酯：一项安全性和对静脉血氨浓度影响的初步研究。
Clin Pharmacol Drug Dev. 2013 Jul;2(3):278-84. doi: 10.1002/cpdd.18. Epub 2013 Mar 16.
9
Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.不可吸收双糖与安慰剂/无干预措施对比，以及乳果糖与乳糖醇对比，用于肝硬化患者肝性脑病的预防和治疗
Cochrane Database Syst Rev. 2016 Apr 18;4:CD003044. doi: 10.1002/14651858.CD003044.pub3.
10
Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy.经颈静脉肝内门体分流术栓塞术治疗内科难治性肝性脑病
Liver Transpl. 2016 Jun;22(6):723-31. doi: 10.1002/lt.24440.